Certara Launches Secondary Intelligence™ Software to Predict Risk of Unwanted Side Effects of Drug Candidates Earlier

First-of-its-kind software predicts likelihood of off-target safety issues that could impede clinical progress PRINCETON, NJ – May 4, 2021, Certara, Inc. (Nasdaq: CERT), the global leader in biosimulation, today announced the launch of its Secondary Intelligence™ software, the first and only software that quantitatively predicts the risk of adverse effects and safety issues derived from … Continued

1 of 1
Back to top
Powered by Translations.com GlobalLink OneLink Software